BioPharma Dive October 24, 2024
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
Derek Wallace was in a dengue-focused intensive care unmet in Thailand in 2009 when he first saw the devastating impact of the disease up close, also known as “breakbone fever.” Facing a shortage of space, children shared beds while parents slept together on mattresses tucked below.
“That’s been the case for decades in some countries,” said Wallace, who was a clinical team leader for Sanofi’s dengue vaccine studies at the time and is now president of Takeda Pharmaceutical’s global vaccine business unit. “But what’s really important is that it’s getting worse. There’s 30 times more dengue than there...
Today's Sponsors
Today's Sponsor